KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) - Pipeline Insight, 2020 - ResearchAndMarkets.com

The "KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) market. A detailed picture of the KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) pipeline landscape is provided, which includes the disease overview and KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) treatment guidelines.

The assessment part of the report embraces in-depth KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) commercial assessment and clinical assessment of the KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) treatment.
• KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) market.

Scope of the Report

• The KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).

Key Topics Covered

1. Report Introduction

2. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE)

2.1. Overview

2.2. History

2.3. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Diagnosis

2.6.1. Diagnostic Guidelines

3. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Current Treatment Patterns

3.1. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Treatment Guidelines

4. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Late Stage Products (Phase-III)

7. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Discontinued Products

13. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Key Companies

15. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Unmet Needs

18. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Future Perspectives

19. KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE) Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/debid6

View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005034/en/